COVID-19 has revolutionized the use of sophisticated technologies in drug development
Filter Categories
All
White Paper
Blog Post
-
The slow uptake of biosimilars in the US market may have lulled some into a false belief that they... -
Pharma leaders need to understand the factors holding assets back from reaching full potential and keep a sense of... -
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by loss of cognitive function (specifically memory loss) and inability to... -
The unmet need in AML continues to be quite high despite the advances in cancer research. -
Innovative brands need to revisit their biosimilar plans to ensure they can maximize their time over the competition -
Most of the therapeutic candidates target rare diseases and cancers which are difficult to treat and do not have... -
The slowdown of recent growth in the Chinese Pharma market demonstrates potential for western companies to partner with their... -
Digital health can speed the identification and approval of agents in oncology, rare diseases, immunology and neurology. -
As ADCs continue to get incorporated in the treatment landscape across several solid tumors, data emerging from the next... -
Chinese pharmaceutical companies present both an opportunity and a threat to their international counterparts. In this blog, we explore... -
The Chinese regulatory landscape is very different compared to that of the rest of the world. Can businesses bridge... -
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they... -
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they... -
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they... -
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they... -
Nature has accepted and published a manuscript from Prescient’s Aakriti Verma in their “Scientific Reports”. This research revealed novel... -
Last year, Prescient embarked upon the ambitious exercise of interviewing competitive intelligence (CI) practitioners across the pharmaceutical industry to... -
How you spend your CI budget is as important as how much you are spending; therefore, it is vital... -
Competitive intelligence (CI) is fundamental to ensuring the success of pharmaceutical companies, whether they are planning a new drug... -
In this white paper, Ben Doran and Jeanne Penn draw on their experiences in the pharmaceutical field to explain... -
Virtual workshops have different planning requirements compared to similar events that might take place face to face. Prescient has... -
Now more than ever, we are facing the question of why we need digital media monitoring (DMM). Competitors are... -
The impact of COVID-19 on clinical and regulatory affairs, manufacturing and supply chains, and stakeholder engagements has slowed the... -
Regulatory agencies across the world are issuing flexible guidelines to cater to the COVID-19 public health emergency. This is... -
Content and offerings are evolving – so should your approach to maximize insights. -
Do you feel that without a physical congress, you are losing an essential tool in understanding the dynamics of... -
The continued rise of COVID-19 is expected to have short- and long-term impacts across the key biopharmaceutical functions, and... -
Prescient has conducted research among competitive intelligence (CI) stakeholders throughout the biopharmaceutical industry to identify the top challenges in... -
In this white paper, Prescient has identified three industry trends that are shaping competitive dynamics in the US market... -
Tumor mutational burden (TMB (the number of mutations per megabase of DNA (mut/Mb)) can be a predictor of response... -
Skin diseases constitute one of the leading causes of health burden worldwide, measured as disability-adjusted life years (DALYs). Among... -
Activating mutations in the EGFR gene are found in about 10-12% of all non-small cell lung cancer (NSCLC) cases... -
Lung cancer is the leading cause of cancer mortality worldwide, accounting for more than 1.6 million deaths annually. Non-small...
-
Breast cancer is the most common cancer in women with more than 2.1 million new cases diagnosed in 2018.... -
With regulatory approval, CAR-T cell therapy must address significant unmet needs in clinical practice without restrictions in order to... -
A largely glossed-over finding from active-controlled trials of checkpoint inhibitors in solid tumors is the delayed crossover of Kaplan-Meier...
-
Access to cancer therapies is a part of every country’s health policy agenda; it, however, is not guaranteed to... -
By: Tanya Casimiro, PhDAs the first Phase III data in non-alcoholic steatohepatitis (NASH) begin to be released, the next... -
There is significant interest in companion diagnostics (CDx) throughout the healthcare industry, but for this personalized medicine approach to... -
Approximately 7,000 rare diseases affect more than 300 million people worldwide, or around 5-8% of the population, depending on... -
On April 16, 2018, data from multiple pivotal trials in first-line (1L) non-small-cell lung cancer (NSCLC) were presented at... -
The US healthcare system has been facing great uncertainty, with ongoing challenges to the sustainability of the Affordable Care...
LinkedIn
Twitter
Facebook